Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody

Ichihara, Seiya; Ogino, Hirokazu; Yoneda, Hiroto; Haji, Keiko; Kagawa, Kozo; Murakami, Kojin; Mima, Masato; Aoi, Yu; Mitsuhashi, Atsushi; Tsukazaki, Yuki; Yabuki, Yohei; Ozaki, Ryohiko; Sato, Seidai; Nokihara, Hiroshi; Nishioka, Yasuhiko

doi:10.1016/j.rmcr.2022.101797

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Larsen et al documented the development of anti-aminoacyl tRNA synthetase (ARS) antibody positive polymyositis at the same time as the induction of CIP by the anti-PD-1 antibody nivolumab, resulting in repeated aggravation of the pneumonitis symptoms and prolonged cycle of the treatment (62). A case report (63) documented that a male patient with antinuclear antibody-negative NSCLC was admitted to the hospital with dyspnea after receiving ICIs administration. On admission, a diagnosis of CIP was made in conjunction with imaging.…”

Section: Autoimmune Diseasesmentioning

confidence: 99%

Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management

Lin,

Zang,

Liu

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The advent of immune-checkpoint inhibitors (ICIs) has revolutionized the treatment of malignant solid tumors in the last decade, producing lasting benefits in a subset of patients. However, unattended excessive immune responses may lead to immune-related adverse events (irAEs). IrAEs can manifest in different organs within the body, with pulmonary toxicity commonly referred to as immune checkpoint inhibitor-related pneumonitis (CIP). The CIP incidence remains high and is anticipated to rise further as the therapeutic indications for ICIs expand to encompass a wider range of malignancies. The diagnosis and treatment of CIP is difficult due to the large individual differences in its pathogenesis and severity, and severe CIP often leads to a poor prognosis for patients. This review summarizes the current state of clinical research on the incidence, risk factors, predictive biomarkers, diagnosis, and treatment for CIP, and we address future directions for the prevention and accurate prediction of CIP.

show abstract

Section: Autoimmune Diseasesmentioning

confidence: 99%